SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pui CH,Relling MV,Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350: 15351548.
  • 2
    Nachman JB,Sather HN,Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 16631671.
  • 3
    Woods WG,Kobrinsky N,Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 49794989.
  • 4
    Arceci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol. 2002; 9: 353360.
  • 5
    Smith MAD,Camitta B,Carroll AJ, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14: 46.
  • 6
    Pui CH,Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166178.
  • 7
    Dworzak MN,Froschl G,Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002; 99: 1952198.
  • 8
    Coustan-Smith E,Ribeiro RC,Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood. 2006; 108: 97102.
  • 9
    Grimwade D,Walker H,Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 10
    Lowdell MW,Lamb L,Hoyle C, et al. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol. 2001; 114: 1124.
  • 11
    Porrata LF,Litzow MR,Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002; 16: 1311138.
  • 12
    Porrata LF,Inwards DJ,Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol. 2002; 117: 629633.
  • 13
    Porrata LF,Ingle JN,Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 2001; 28: 865871.
  • 14
    Porrata LF,Gertz MA,Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001; 98: 579585.
  • 15
    Behl D,Porrata LF,Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006; 20: 2934.
  • 16
    Hudson G,Lomas C,Manley S, et al. Lymphocyte regeneration predicts improved survival in childhood acute lymphoblastic leukaemia [abstract]. Presented at: American Society of Hematology 45th Annual meeting and Exposition, December 6–9, 2003, San Diego, California; Poster Session 503-I. Blood (ASH Annual Meeting Abstracts). 2003; 102. Abstract 1391.
  • 17
    Lomas C,Hudson G,Manley S, et al. Regeneration predicts improved survival in childhood acute myeloid leukaemia [abstract]. Presented at: American Society of Hematology 45th Annual meeting and Exposition, December 6–9, 2003, San Diego, California; Poster Session 470-III. Blood (ASH Annual Meeting Abstracts). 2003; 102. Abstract 3250.
  • 18
    Thomas DA,O'Brien S,Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004; 104: 16241630.
  • 19
    Kantarjian H,Thomas D,O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 27882801.
  • 20
    Kern W,Schleyer E,Unterhalt M, et al. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer. 1997; 79: 5968.
  • 21
    Woods WG,Neudorf S,Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001; 97: 5662.
  • 22
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 23
    Cox DR. Regression models and life tables. J Roy Stat Soc. 1972; 34: 187220.
  • 24
    Razzouk BI,Estey E,Pounds S, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006; 106: 24952502.
  • 25
    Faderl S,Thall PF,Kantarjian HM, et al. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002; 117: 869874.
  • 26
    Faderl S,Estrov Z. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma. 2004; 45: 6771.
  • 27
    Onciu M,Estey E,Giles FJ. Circulating blasts following chemotherapy in pediatric patients: implications for complete remission definition in acute leukemia. Hematology. 2003; 8: 295301.
  • 28
    Spruance SL,Reid JE,Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agent Chemother. 2004; 48: 27872792.
  • 29
    Lowdell MW,Craston R,Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002; 117: 821827.
  • 30
    Ohnishi K,Yamanishi H,Naito K, et al. Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia. Leukemia. 1998; 12: 5258.
  • 31
    Wiegering VA,Eyrich M,Schlegel PG,Winkler B. Changes in the immune functions during ALL induction therapy—prospective immune monitoring in 23 children [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 4519.
  • 32
    Komada Y,Zhang SL,Zhou YW, et al. Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy. Cancer Immunol Immunother. 1992; 35: 271276.
  • 33
    Porrata LFGD,Padley D,Bundy K,Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma. 2003; 44: 9971000.
  • 34
    Lake RA,Robinson BW. Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer. 2005; 5: 397405.
  • 35
    Nowak AK,Robinson BW,Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002; 62: 2353238.
  • 36
    Su YB,Sohn S,Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004; 22: 610616.
  • 37
    Tsavaris N,Kosmas C,Vadiaka M, et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002; 87: 2127.
  • 38
    Howard SC,Ribeiro RC,Pui CH. Strategies to improve outcomes of children with cancer in low-income countries. Eur J Cancer. 2005; 41: 1584157.
  • 39
    Eden T,Pui CH,Schrappe M, et al. All children have a right to full access to treatment for cancer. Lancet. 2004; 364: 1121112.
  • 40
    Pui CH,Ribeiro RC. International collaboration on childhood leukemia. Int J Hematol. 2003; 78: 383389.
  • 41
    De Angulo G,Hernandez M,Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing's sarcoma. J Pediatr Hematol Oncol. 2007; 29: 4852.